Regenerative medicine of pancreatic islets  

作　　者：Irina V Arutyunyan Timur Kh Fatkhudinov Andrey V Makarov Andrey V Elchaninov Gennady T Sukhikh 

机构地区：[1]National Medical Research Center for Obstetrics,Gynecology and Perinatology named after Academician V.I.Kulakov of Ministry of Healthcare of Russian Federation,Moscow 117997,Russia [2]Research Institute of Human Morphology,Moscow 117418,Russia [3]Peoples Friendship University of Russia,Moscow 117198,Russia [4]Pirogov Russian National Research Medical University,Ministry of Healthcare of the Russian Federation,Moscow 117997,Russi

出　　处：《World Journal of Gastroenterology》2020年第22期2948-2966,共19页世界胃肠病学杂志（英文版）

基　　金：Supported by the President Grant for Government Support of Young Russian Scientists,No.075-15-2019-1120.

摘　　要：The pancreas became one of the first objects of regenerative medicine,since other possibilities of dealing with the pancreatic endocrine insufficiency were clearly exhausted.The number of people living with diabetes mellitus is currently approaching half a billion,hence the crucial relevance of new methods to stimulate regeneration of the insulin-secretingβ-cells of the islets of Langerhans.Natural restrictions on the islet regeneration are very tight;nevertheless,the islets are capable of physiological regeneration viaβ-cell self-replication,direct differentiation of multipotent progenitor cells and spontaneousα-toβ-orδ-toβ-cell conversion(trans-differentiation).The existing preclinical models ofβ-cell dysfunction or ablation(induced surgically,chemically or genetically)have significantly expanded our understanding of reparative regeneration of the islets and possible ways of its stimulation.The ultimate goal,sufficient level of functional activity ofβ-cells or their substitutes can be achieved by two prospective broad strategies:β-cell replacement andβ-cell regeneration.The“regeneration”strategy aims to maintain a preserved population ofβ-cells through in situ exposure to biologically active substances that improveβ-cell survival,replication and insulin secretion,or to evoke the intrinsic adaptive mechanisms triggering the spontaneous non-β-toβ-cell conversion.The“replacement”strategy implies transplantation ofβ-cells(as non-disintegrated pancreatic material or isolated donor islets)orβ-like cells obtained ex vivo from progenitors or mature somatic cells(for example,hepatocytes orα-cells)under the action of small-molecule inducers or by genetic modification.We believe that the huge volume of experimental and clinical studies will finally allow a safe and effective solution to a seemingly simple goal-restoration of the functionally activeβ-cells,the innermost hope of millions of people globally.

关 键 词：PANCREAS Islets of langerhans β-cells REGENERATION REPLACEMENT TRANSPLANTATION REPROGRAMMING 

分 类 号：R587[医药卫生—内分泌]